You are here » Home » Companies » Company Overview » Sakar Healthcare Ltd

Sakar Healthcare Ltd.

BSE: 538377 Sector: Health care
NSE: SAKAR ISIN Code: INE732S01012
BSE 05:30 | 01 Jan Sakar Healthcare Ltd
NSE 00:00 | 25 Nov 235.30 -0.25
(-0.11%)
OPEN

236.60

HIGH

238.25

LOW

232.60

OPEN
PREVIOUS CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr) 0
Buy Price
Buy Qty
Sell Price
Sell Qty
OPEN
CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr) 0
Buy Price
Buy Qty
Sell Price
Sell Qty

Sakar Healthcare Ltd. (SAKAR) - Chairman Speech

Company chairman speech

Dear fellow Shareholders

My warm greeting to you all!

I am very happy to interact with you as I present the annual report along withfinancial statements of your Company for the fiscal2020-21.

The dramatic events of2020 which have continued into 2021 have tested the world in waysfew anticipated. These events also tested the resilience of our workforce businessoperations and our financial strength. While this has been a very challenging year it hasmade us and our business stronger and we are very well prepared as we move into the nextyear.

Despite the economic slowdown and the unprecedented situation posed by CoVID-19fundamentally the outlook for the India Pharmaceutical Industry remains positive. Thelong-term growth driven by higher pharma exports as countries across the globe increasetheir health spends remains intact.

LOOKING INTO THE FUTURE

Sakar future growth would be driven by the following:

Increase High Margin Exports

Sakar's exports have grown by over 2.3 times in the last three years and is expected tocontinue to grow at a fast clip as the driven by company's push into regulated markets.The company last year received EU GMP for its Liquid & Lyophilized injectable facilitywhich will open up regulated markets for it. Exports contribute 80% of company's EBITDA.In addition with commencement of Oncology plant exports will get further fillip thuspositively impacting margins across the board.

Oncology (anti-cancer) unit to drive exponential growth

Entry into the fastest growing therapeutic segment with high barriers to entry willgive a big fillip to company's growth for the next many years. This state of the artmanufacturing facility has been designed according to the USFDA standards and will helpthe company to sell its Onco products into regulated markets.

With strong business fundamentals the company is very well placed to ride out theCoVID-19 storm. We will continue to innovate and adopt adapt to remain ahead of the curve.

Before concluding on behalf of the Board and management I would like to thank ourshareholders customers distributors and other stakeholders for their continued supportand trust in us. We would continue our endeavors to build a future-ready dynamic andtrustworthy organization which will help us achieve the next level of business growth andvalue creation.

It is an honor to serve you all.

With Warm Regards

Sd/-

SANJAY SHAH

Chairman and Managing Director

.